Research on the drugs used to treat cancer and how well they work. Covers immunotherapy, chemotherapy-free regimens, biosimilars, targeted drugs, and treatment costs.
The study found that cancer cells become less stiff after exposure to chemotherapy drugs, but the rate of stiffness change decreases under hypoxic conditions. Alteration in cytoskeletal structure influences overall cell functions, including signaling, communication, adhesion, transport, and tumor metastasis.
A McMaster-led study found that abelacimab prevents blood clots for up to a month after surgery, reducing the risk by about 80% compared to enoxaparin. The treatment also has potential to treat other cardiovascular conditions, such as stroke and deep-vein thrombosis.
Researchers developed patient-specific tumor organoids to test immunotherapy treatments for appendiceal cancer. The study found that various types of immunotherapies can achieve personalized results, identifying beneficial treatments while sparing patients from harmful side effects.
Scientists at Sinai Health discover that all cancers fall into two categories based on the presence or absence of YAP. This binary rule reveals different drug sensitivities and resistance in each classification, offering a new strategy for treating aggressive forms of cancer.
Zeynep Eroglu, MD, assistant member of the Cutaneous Oncology Department at Moffitt Cancer Center, received the 2021 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute. The award recognizes outstanding clinical investigators working to improve cancer care.
The Zero Childhood Cancer Program, a precision medicine program, has received a $600k donation from The Lott to enhance research capabilities and provide personalized treatment plans to children with high-risk cancer. Over 70% of enrolled patients have shown a response, with some tumours stabilized or shrunk.
Researchers found that combining low-dose radiation with immunotherapy significantly boosts cancer eradication rates in mice. The treatment approach triggers the immune system to attack cancer cells, even when radiation alone is too weak to destroy them.
Researchers have developed a new type of nanocarrier that combines photothermal, chemo-therapy, and chemodynamic therapy to target and destroy cancer cells. The nanoclusters, which are responsive to near-infrared light, show a significant inhibitory effect on mouse tumor growth in vivo experiments.
Research found that adult patients under 65 had less trouble paying for medications, dental care, and delayed treatment due to cost. The ACA's key features, including the Health Insurance Marketplace, led to a significant decrease in financial burdens.
The Lewis Katz School of Medicine at Temple University has received a $1 million T32 predoctoral training grant from the National Institute of General Medical Sciences. The grant aims to provide students with opportunities for training in cell signaling, epigenetics, and genome maintenance.
A new study found that using an existing immunotherapy drug for late-stage kidney cancer at an earlier stage can reduce the risk of cancer returning by a third. The KEYNOTE study involved over 1000 patients and showed similar side effects to other cancer treatments.
Researchers have identified a new generation of anti-cancer drugs that target aggressive childhood brain tumors. The genetic map of these tumours has helped predict the effectiveness of existing drugs, including Ixabepilone, in treating medulloblastoma.
A recent study published by the European Society of Cardiology found that older patients with heart failure are less likely to receive recommended therapies and dosages compared to their younger counterparts. The study analyzed data from the Swedish Heart Failure Registry and found that age was independently associated with undertreatm...
A study at ECCMID identifies existing drugs that could be repurposed to treat gonorrhoea by targeting efflux pumps, which remove toxic compounds from bacterial cells. The research found 57 potential drug candidates, including dequalinium and doxorubicin, which may serve as lead compounds for new gonorrhea treatments.
Researchers at Tel-Aviv University have developed a targeted delivery system for RNA-based drugs that selectively targets diseased cells without harming healthy ones. The breakthrough has potential implications for various diseases, including blood cancers and inflammatory conditions.
Researchers have developed a chemical compound that produces a powerful oxygen reaction when exposed to light, selectively killing cancer cells while leaving surrounding tissue intact. The photodrug is currently in clinical trials for patients with recurring bladder cancer resistant to traditional therapies.
A 18-year follow-up study of babies born from treatments including ICSI and frozen embryo transfer found no increased cancer risk in ART-conceived offspring. The study compared outcomes between ART children and those conceived naturally or with fertility drugs, concluding that there is no overall increase in cancer risk for those born ...
A new approach to molecular drug design has yielded a highly promising bladder cancer treatment candidate that induces rapid shedding of tumour cells and results in significant tumour size reduction. The treatment shows potent effects on patients with non-muscle invasive bladder cancer, demonstrating safety without side effects.
A nationwide study evaluates a targeted intervention aimed at transforming e-cigarettes from a maintenance product to a tool for smoking cessation. The research shows that the intervention produced smoking abstinence rates about 5-10 percentage points higher than those who received no intervention.
Researchers found that HER3 gene mutations can amplify activity of a protein that spurs tumor growth in breast cancer. A new study suggests that targeting this protein may lead to more effective treatments for patients with both HER2 and HER3 mutations.
A new online database, TOPOGRAPH, has been developed to streamline the process of recommending therapeutic treatments in precision cancer medicine for Australian patients. The platform catalogues oncology research and provides personalized treatment recommendations based on genomic variations and biomarkers.
MADM technology has been expanded to enable the analysis of over 96% of mouse genes at the single-cell level. This breakthrough allows researchers to study disease progression, including cancer, and gain insights into gene function.
Researchers discovered that pancreatic cancer cells use a backup protein complex to survive when KRAS is blocked, allowing them to continue growing and dividing. This finding highlights the need for drugs that can target multiple molecules in cancer cells to improve treatment outcomes.
A large study of over 1.8 million women has found no link between fertility drugs and an increased risk of breast cancer. The research, published in Fertility and Sterility journal, provides reassurance to women seeking fertility treatments.
Researchers found novobiocin selectively killed tumor cells with abnormal BRCA1 or BRCA2 genes. The drug is effective even in tumors resistant to PARP inhibitors, which are a prime therapy for cancers with DNA-repair glitches.
Researchers identified a new class of POLQ inhibitors that specifically kill cancer cells with mutations in the BRCA genes while leaving healthy cells unharmed. The drugs show promise in treating cancers such as breast, ovarian, pancreatic, and prostate cancer with BRCA mutations.
Dr. Larson has been named recipient of the prestigious Paul C. Aebersold Award for his contributions to cancer imaging and radionuclide therapy. He is a world-renowned expert in radiopharmaceutical therapy and molecular imaging.
Researchers discovered a targeted drug, AT7519, effective in thwarting pancreatic tumors addicted to mutant KRAS gene. The study found that this CDK inhibitor selectively kills mutant KRAS-addicted cancer cells.
Scientists at Rockefeller University have identified a new class of therapeutics that destroy fibrolamellar tumor cells growing in mice. The team tested over 5,000 compounds to find these effective treatments, which could potentially transform the landscape of precision medicine by tailoring treatment options for individual patients
Researchers discovered that MAOIs can activate the immune system to shrink various types of tumors. The study found that MAOIs help block immune checkpoints and prevent tumor-associated macrophages from suppressing T cell activity.
Researchers at RUDN University developed an eco-friendly method to synthesize pyrrole and pyrazole derivatives, which exhibit fluorescent properties. The new process is safer, cheaper, and more efficient, generating a wide range of bioactive compounds with potential applications in medicine.
Researchers identified neutrophil elastase as a major anti-cancer protein that activates cell death pathways specifically in cancer cells. This discovery may lead to the development of first-in-class medicines that target cancer cells while sparing healthy tissues.
Duke University engineers developed a prototype X-ray scanner that can reveal molecular composition of objects, revolutionizing cancer surgery, pathology, drug inspection, and geology. The technology can accurately diagnose cancerous tissues and analyze pharmaceuticals in real-time.
A new study by Ludwig Institute researchers has developed a method to quickly identify potentially effective drug combinations for personalized cancer therapy. By using dynamic BH3 profiling, the team found specific metabolic dependencies in triple-negative breast cancer cells that could be targeted with existing drugs.
A team of researchers identifies how the cowpea mosaic plant virus is recognized by the immune system and strongly stimulates it to attack and eliminate cancerous tumors. The discovery opens the door for CPMV to be pursued as a new biological drug for treatment of cancer.
The FDA-approved drug sotorasib has been shown to reduce tumor size and improve survival among patients with non-small-cell lung cancer caused by a specific DNA mutation. The study involved 126 patients who showed significant responses to the treatment, including 34% achieving partial response and 3% complete response.
A new drug, sotorasib, has shown significant benefit in treating non-small-cell lung cancer patients with a specific KRAS mutation. The study found that 37.1% of patients experienced tumor shrinkage and 82% saw slowing of tumor growth.
Researchers found that nivolumab significantly reduced bladder cancer recurrence after surgery in high-risk patients. Disease-free survival was 21 months for nivolumab recipients compared to 10.9 months for placebo recipients.
A national survey of breast cancer patients and oncologists reveals that nearly three-quarters of patients use complementary medicine during treatment, yet doctors often fail to discuss integrative health with patients. Patients report finding hope and improving quality of life through these therapies.
A new study published in Nature reveals that a commonly used psychiatric drug can boost the fitness of healthy gut stem cells, making them more resistant to cancer. A clinical trial is now underway to investigate whether lithium can prevent bowel cancer in individuals with familial adenomatous polyposis (FAP).
A global review found that Opioid Agonist Therapy (OAT) is associated with lower risk of multiple causes of death among people with opioid dependence. OAT was linked to reduced overdose-related, suicide, alcohol-related, cancer, and cardiovascular-related mortality.
Researchers from SWOG presented results on several studies, including S1216 and S1404, which showed promising findings for patients with prostate and melanoma cancers. Additionally, secondary analyses from S0809 and S1200 revealed benefits of adjuvant chemoradiation and acupuncture for certain cancer types.
Australian scientists have discovered a new and effective way to treat high-risk blood cancer in children. A combination of ruxolitinib with commonly used anticancer drugs showed enhanced treatment efficacy in two out of three patient-derived xenograft models, achieving long-term suppression of leukaemia growth.
Researchers found that certain drugs can alter cell mechanical properties without reducing effectiveness, allowing for lower doses. The study used atomic force microscopy to measure cell rigidity and actin filament activity, enabling precise determination of optimal drug concentrations.
University of Virginia researchers have developed a new computational method to map the folding patterns of chromosomes in three dimensions. This will help scientists understand the genetic cause of cancer and advance other areas of medical research.
Even among insured individuals, up to 10% of cancer survivors delayed follow-up care due to financial constraints. Financial stress and anxiety hinder timely survivorship care, particularly among vulnerable populations such as racial minorities, women, and those with lower incomes.
MUSC researchers develop peptide siRNA carriers that improve gene silencing and deliver siRNA into cancer cells. The modified carriers, such as RD3AD, use filopodia entry to efficiently deliver the therapeutic molecules.
Researchers found that obesity-associated metabolic factors activate myeloid-derived suppressor cells, which can enhance cancer risk. Additionally, a prospective cohort study revealed meaningful differences in cancer risk by race and sex among obese adults.
Researchers at UC Riverside developed an implantable drug delivery system using piezoelectric nanofibers that can release therapeutic molecules on demand. The system offers robust control over release rate and precision in administering drug molecules, making it suitable for treating chronic diseases.
A dental school researcher has received FDA approval to begin clinical trials for a new cancer therapy using a protein found in an oral bacterium. The treatment, Leukothera, rapidly kills cancer cells without compromising the immune system, offering a potential alternative to existing treatments.
Researchers have developed a prognostic and therapeutic epigenetic biomarker for PDAC patients, predicting which are likely to benefit from traditional chemotherapy. The technology addresses a pressing clinical need by introducing the first ever epigenetic precision medicine approach to pancreatic cancer.
Decitabine, used to treat blood cancers like MDS and AML, works by activating endogenous retroviruses that induce an immune response. The study found two key gene sequences involved in this process, Staufen1 and TINCR, whose expression levels determine a patient's response to the drug.
Researchers at Dana-Farber Cancer Institute presented numerous studies on various types of cancer, including kidney cancer, melanoma, and lung cancer. The studies focused on innovative treatments, diagnostic advances, and patient outcomes.
Researchers developed two experimental drug approaches targeting cancer cell metabolism, showing promise in treating highly aggressive pediatric brain cancer. The treatments extended survival and enhanced effectiveness of standard chemotherapies in patients with MYC-amplified medulloblastoma.
A new study led by UT Southwestern scientists shows that an experimental drug, avasopasem manganese (AVA), enhances radiation's capacity to kill tumors while protecting healthy tissue from collateral damage. The findings could provide a much-needed boost to radiation treatments used against various tumor types.
The GEM ExTra test uses whole exome sequencing and RNA sequencing to detect actionable mutations in patients with advanced solid tumors. It has been validated through clinical utilization and provides clinically actionable information to guide patient management decisions.
In a Phase I trial, IACS-6274 demonstrated successful target inhibition and early signs of anti-tumor activity in 60% of evaluable patients. Durable disease stabilization was observed in six patients with biomarker-defined advanced cancers.
A fixed-dose combination of nivolumab and relatlimab demonstrated a statistically significant benefit over anti-PD-1 monotherapy in metastatic melanoma. The study found that patients treated with the combination therapy had a median progression-free survival of 10.1 months, compared to 4.6 months for those treated with nivolumab alone.
A new study suggests that cardioprotective drugs during adjuvant breast cancer therapy may not be necessary for most patients, especially those at low risk of heart disease. The research found no significant differences in heart function between patients who received these medications and placebos.
University of Alberta scientists have identified Toll-like receptor 4 as a potential target for preventing permanent hearing loss caused by the chemotherapy drug cisplatin. By inhibiting this receptor, they may be able to eliminate toxic side effects from the drug that cause hearing loss in childhood cancer survivors.